Clinical Trials Browser

Withdrawn × Hematologic Neoplasms × Brentuximab Vedotin × Clear all

NCT04138875 2022-06-23

A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)

Phase 2 Withdrawn

Other hematologic neoplasm

Infectious Mononucleosis, Hematologic Neoplasms

NCT01620229 2014-04-21

Brentuximab Vedotin After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Phase 1/2 Withdrawn

Other hematologic neoplasm

Hematologic Neoplasms